ICON plc
ICON plc is a global provider of clinical, consulting, and commercial services, dedicated to helping pharmaceutical, biotechnology, and medical device companies bring new drugs and devices to market faster. The company offers a comprehensive range of services that span the entire lifecycle of product development, from early clinical phases to post-marketing. ICON is committed to delivering high-quality, harmonized data and innovative solutions to improve patient recruitment, retention, and engagement, while ensuring regulatory compliance and operational efficiency.
ICON plc
2100 Pennbrook Parkway, North Wales, PA 19454, USA
What We Do
ICON offers bespoke, seamless solutions to meet unique sponsor challenges, providing agile, adaptable outsourcing models that fit evolving needs in a dynamic clinical research landscape.
Ensuring the highest levels of safety and accuracy in clinical trials, ICON provides end-to-end cardiac safety solutions, including ECG, event monitoring, BPM, long-term Holter monitoring, ECHO, and MUGA studies.
Specializing in the planning, management, execution, and analysis of Phase 2-3 clinical trials, ICON provides a flexible approach to improve cycle times, constrain costs, and reduce risks.
ICON offers end-to-end services, operational models, and technology to deliver customized solutions for decentralized clinical trials, improving patient recruitment, retention, and diversity.
ICON specializes in early phase development services, enabling informed decision-making for drug development programs with a focus on clinical pharmacology and volunteer recruitment.
ICON provides flexible, agile, and proactive laboratory solutions dedicated to global clinical development, offering bioanalytical, central, and specialty laboratory services.
News & Updates
Using exclusive data from ICON’s 2023 survey with Citeline, this report presents valuable insights from 133 influential decision-makers within biotech and venture capital organisations from across North America, Europe, and Asia Pacific.
This whitepaper describes the rigorous, iterative linguistic validation process for COAs that ensures conceptual equivalency and cultural relevance for each required translation.
This whitepaper discusses the transition from paper to electronic versions of documents in clinical research to improve participant experience and data quality.
This whitepaper details the prerequisites for controlled use of Clinical Outcome Assessments (COAs) and suggestions for streamlining the licensing process.
This whitepaper describes the adoption of an eCOA solution and shares a recommended approach to planning and implementing eCOA to mitigate risks of delaying study start-up.
This whitepaper suggests a design overhaul for scientific posters to make a lasting impression during poster sessions.